ArticleGeneral published source
- Source type
- Article
- Access type
- Publisher
- Publisher
- Servier
- Date
- 2026-06-25
- Added
- 2026-06-27
Trust profile
60
General published source
- Publisher type
- General media
- Bias profile
- Elevated
Best used for
- Context
- Public narrative
Weak for
- Clinical claims
- Safety conclusions
- Regulatory status
Used in Viral Vitalism
This source is in the canonical library but is not yet connected to a published page.
Claims supported
No reusable evidence claims are currently attached to this source.
Related studies
No structured study record is currently attached to this source.
Related sources
GovernmentU.S. health regulator
FDA: Draft Guidance to Help Accelerate Cell and Gene Therapies
Canonicalized from rapid brief fda-rare-disease-gene-therapy-flexibility.
- Trust score
- 94
- Publisher
- U.S. Food and Drug Administration
- Access
- Official
- Usage
- 1 connection
GovernmentU.S. health regulator
FDA: Leveraging Prior Knowledge in Gene Therapy Products Incorporating Genome Editing
Canonicalized from rapid brief fda-rare-disease-gene-therapy-flexibility.
- Trust score
- 94
- Publisher
- U.S. Food and Drug Administration
- Access
- Official
- Usage
- 1 connection
GovernmentU.S. health regulator
FDA: First Gene Therapies to Treat Patients with Sickle Cell Disease
Canonicalized from rapid brief daniel-cressy-sickle-cell-gene-therapy-louisiana.
- Trust score
- 94
- Publisher
- U.S. Food and Drug Administration
- Access
- Official
- Usage
- 2 connections
GovernmentU.S. health regulator
FDA: First Over-the-Counter Continuous Glucose Monitor for Children
Canonicalized from rapid brief fda-otc-cgm-children-dexcom-stelo.
- Trust score
- 94
- Publisher
- U.S. Food and Drug Administration
- Access
- Official
- Usage
- 1 connection
ArticleGeneral published source
Solid Biosciences: June 2026 Duchenne community letter
Canonicalized from rapid brief duchenne-youngest-microdystrophin-gene-therapy-sgt003.
- Trust score
- 60
- Publisher
- Solid Biosciences
- Access
- Publisher
- Usage
- 1 connection
ArticleGeneral published source
Regenxbio: Alignment with FDA on path forward for Navsunli BLA resubmission
Canonicalized from rapid brief regenxbio-navsunli-rgx-121-fda-accelerated-approval-path.
- Trust score
- 60
- Publisher
- Regenxbio
- Access
- Publisher
- Usage
- 1 connection
Topic tags
medicineclinical-trialsrare-diseasepediatric-medicineepilepsyantisense-oligonucleotide